94 related articles for article (PubMed ID: 9816309)
1. TIMP1 and adverse prognosis in non-small cell lung cancer.
Fong KM; Kida Y; Zimmerman PV; Smith PJ
Clin Cancer Res; 1996 Aug; 2(8):1369-72. PubMed ID: 9816309
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TIMP-1 in non-small cell lung cancer.
Pesta M; Kulda V; Kucera R; Pesek M; Vrzalova J; Liska V; Pecen L; Treska V; Safranek J; Prazakova M; Vycital O; Bruha J; Holubec L; Topolcan O
Anticancer Res; 2011 Nov; 31(11):4031-8. PubMed ID: 22110238
[TBL] [Abstract][Full Text] [Related]
4. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
[TBL] [Abstract][Full Text] [Related]
5. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
9. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer.
Safranek J; Holubec L; Topolcan O; Pesta M; Klecka J; Vodicka J; Finek J; Kormunda S; Pesek M
Anticancer Res; 2007; 27(4C):2953-6. PubMed ID: 17695477
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
[TBL] [Abstract][Full Text] [Related]
11. Expression of transcription factor Pokemon in non-small cell lung cancer and its clinical significance.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Fu K; Zhang J
Chin Med J (Engl); 2008 Mar; 121(5):445-9. PubMed ID: 18364119
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
[TBL] [Abstract][Full Text] [Related]
14. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
17. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
18. High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters.
Hakuma N; Betsuyaku T; Kinoshita I; Itoh T; Kaga K; Kondo S; Nishimura M; Dosaka-Akita H
Oncology; 2007; 72(3-4):197-204. PubMed ID: 18160808
[TBL] [Abstract][Full Text] [Related]
19. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line.
Jee BK; Park KM; Surendran S; Lee WK; Han CW; Kim YS; Lim Y
Biochem Biophys Res Commun; 2006 Apr; 342(2):655-61. PubMed ID: 16488391
[TBL] [Abstract][Full Text] [Related]
20. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
